VHL rs121913343: What Your Genotype Means
The rs121913343 variant is an ultra-rare single nucleotide variation located within the VHL tumor suppressor gene. When present in a heterozygous state, it is cataloged as predisposing individuals to von Hippel-Lindau (VHL) disease, a hereditary cancer syndrome characterized by an increased lifetime risk of clear cell renal carcinomas, pheochromocytomas, and central nervous system hemangioblastomas. In the general global population, the standard reference allele is overwhelmingly conserved.
What each genotype means
| Genotype | What the research suggests | Reading |
|---|---|---|
| Reference / Reference (Homozygous Wild-Type) | You carry two normal copies of the VHL gene at this position. This is the standard, expected genotype found in virtually the entire global population and is not associated with inherited von Hippel-Lindau disease. | Favorable |
| Reference / Variant (Heterozygous) | You carry one reference copy and one rare variant copy of the VHL gene. In clinical databases, this alteration is categorized as predisposing to von Hippel-Lindau disease and its associated tumor risks, though confirmation by clinical-grade sequencing is required. | Higher attention |
| Variant / Variant (Homozygous Alternate) | Homozygous loss-of-function variants in the VHL tumor suppressor gene are exceedingly rare and typically incompatible with normal embryonic development. Any consumer report showing this genotype is almost certainly an assay artifact that requires clinical evaluation. | Higher attention |
What is rs121913343 and Where is It Found?
The identifier rs121913343 refers to a specific genetic locus within the VHL gene on chromosome 3. The human genome contains two copies of each autosomal gene, one inherited from each biological parent. The VHL gene consists of three coding exons that produce the von Hippel-Lindau tumor suppressor protein (pVHL). At the molecular level, rs121913343 represents a germline alteration in this sequence. While the vast majority of individuals carry the standard reference sequence at this position, rare nucleotide substitutions here can disrupt the reading frame or alter critical amino acid residues in the translated protein. Variants at this locus are curated in clinical registries such as ClinVar and dbSNP to document their relationship to inherited disease. Because the variant lies within a high-impact tumor suppressor, alterations at this genomic position have been tracked in familial cancer genetics to distinguish benign background diversity from disease-associated mutations.
The Biological Role of the VHL Tumor Suppressor Gene
The VHL gene encodes the pVHL protein, which forms an essential component of a multiprotein ubiquitin ligase complex known as the VCB-CUL2 complex. Under normal physiological conditions with adequate cellular oxygen, pVHL recognizes and binds to hypoxia-inducible factor (HIF) alpha subunits that have undergone prolyl hydroxylation. Once bound, the complex tags HIF alpha for rapid degradation by the 26S proteasome. When pVHL function is impaired due to pathogenic germline mutations, HIF alpha escapes degradation and accumulates within the nucleus regardless of oxygen availability. This dysregulation drives continuous transcription of downstream angiogenic and growth factors, such as vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF). In cells that subsequently lose the remaining functional copy of VHL through a somatic 'second-hit' event, unconstrained cellular proliferation, abnormal vascular remodeling, and tumorigenesis can occur.
Health Associations and Strength of Evidence
Germline variants in the VHL gene, including pathogenic alleles mapped to rs121913343, are primarily associated with von Hippel-Lindau disease. Clinically, VHL syndrome is characterized by an elevated lifetime risk of developing clear cell renal cell carcinomas, retinal angiomas, central nervous system hemangioblastomas, pancreatic neuroendocrine tumors, and catecholamine-secreting pheochromocytomas. However, current catalog evidence for this specific variant is characterized as limited due to its extreme scarcity in published literature and general genomic databases. Tumor manifestation in VHL disease follows an autosomal dominant inheritance pattern with incomplete penetrance and variable expressivity. Additionally, the clinical presentation often depends on the specific biophysical impact of the mutation, traditionally grouped into Type 1 (low risk of pheochromocytoma) and Type 2 (high risk of pheochromocytoma) phenotypes, though these classifications serve primarily academic rather than diagnostic roles.
Understanding Your Results: What You Can and Cannot Do
Identifying an ultra-rare variant like rs121913343 in consumer genetic testing requires careful context and verification. Raw consumer DNA data often utilizes microarray technologies that are prone to false-positive calls when probing extremely rare loci. Consequently, unverified data cannot diagnose von Hippel-Lindau disease or confirm active cancer. If an atypical genotype is reported, the essential next step is formal clinical consultation with a genetic counselor or medical geneticist. These specialists can order clinical-grade Sanger sequencing or next-generation sequencing in an accredited diagnostic laboratory to validate the finding. If confirmed pathogenic, established medical guidelines dictate comprehensive, early-onset surveillance protocols—such as routine abdominal imaging, retinal examinations, and biochemical screening for metanephrines—to detect and manage associated neoplasms before they cause complications.
How common is this variant?
The rs121913343 variant is an ultra-rare pathogenic allele with a global minor allele frequency (MAF) of less than 0.00001 in gnomAD, meaning it is absent or detected only in isolated individuals across worldwide reference populations.
Frequently asked questions
Does having the rs121913343 variant mean I will definitely develop cancer?
No. While pathogenic VHL variants significantly elevate the lifetime risk of clear cell renal carcinomas and pheochromocytomas, disease penetrance is incomplete. Developing a tumor requires an acquired, somatic second-hit mutation in the normal VHL allele within specific tissues.
Can consumer genetic kits reliably identify rs121913343?
Consumer microarrays frequently produce false-positive results for ultra-rare variants like rs121913343. Any finding in raw genomic data should be viewed skeptically until independently validated using clinical-grade diagnostic sequencing.
How is von Hippel-Lindau disease passed down through families?
VHL disease follows an autosomal dominant inheritance pattern, meaning that an affected individual has a 50% chance of passing the variant allele to each biological child. However, up to 20% of cases arise from new (de novo) mutations without a family history.
What medical screening is recommended if a VHL mutation is confirmed?
Individuals with confirmed pathogenic VHL variants typically follow structured surveillance protocols starting in childhood. These include periodic blood pressure checks, biochemical screening for pheochromocytomas, dilated eye exams, and routine abdominal and central nervous system imaging.
Sources & further reading
Educational information only, last refreshed 9/5/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs121913343?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29